EGRX News and Press, Eagle Pharmaceuticals Inc. From 05/09/23

2023-05-09 12:59:04 ET Eagle Pharmaceuticals, Inc. ( EGRX ) Q1 2023 Earnings Conference Call May 9, 2023 8:30 am ET Corporate Participants Lisa Wilson - Investor Relations Scott Tarriff - President and Chief Executive Officer Brian Cahill - Chief Financial Of...

2023-05-09 06:55:18 ET Eagle Pharmaceuticals press release ( NASDAQ: EGRX ): Q1 Non-GAAP EPS of $1.26 beats by $0.27 . Revenue of $66.3M (-42.8% Y/Y) beats by $2.97M . Q1 2023 net sales of PEMFEXY totaled $22.9 million; Eagle estimates that it has an appro...

Total revenue for Q1 2023 was $66.3 million, compared to $115.9 million in Q1 2022 Q1 2023 net income was $0.44 per basic and diluted share and adjusted non-GAAP net income 1 was $1.27 per basic and $1.26 per diluted share Q1 2023 adjusted non-GAAP EBITDA of $22.3 million Q1 2023 ...

2023-05-08 13:09:44 ET Eagle Pharmaceuticals ( NASDAQ: EGRX ) is scheduled to announce Q1 earnings results on Tuesday, May 9th, before market open. The consensus EPS Estimate is $0.99 (-71.0% Y/Y) and the consensus Revenue Estimate is $63.33M (-45.4% Y/Y). Over the las...

-- Byfavo 1 is indicated for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less WOODCLIFF LAKE, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company&#x...

WOODCLIFF LAKE, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its first quarter 2023 financial results on Tuesday, May 9, 2023, before the market opens. ...

2023-04-05 12:12:39 ET Eagle Pharmaceuticals ( NASDAQ: EGRX ) said it had reached a settlement agreement with Dr. Reddy’s Laboratories, under which the latter has the right to market its product beginning November 17, 2027, or earlier based on certain circumstances. ...

WOODCLIFF LAKE, N.J., April 05, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has reached a settlement agreement with Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratories, Inc...

2023-03-13 10:45:06 ET Eagle Pharmaceuticals, Inc. (EGRX) Q4 2022 Earnings Conference Call March 13, 2023 8:30 AM ET Company Participants Lisa Wilson - Investor Relations Scott Tarriff - President and Chief Executive Officer Brian Cahill - Chief Financial Officer...

2023-03-13 06:54:27 ET Eagle Pharmaceuticals press release ( NASDAQ: EGRX ): Q4 Non-GAAP EPS of $1.11 beats by $0.28 . Revenue of $60.7M (+43.4% Y/Y) misses by $3.56M . Q4 2022 RYANODEX net product sales were $7.2 million, compared to $6.1 million in the...